Qual é o preço para TCR2 Therapeutics Inc. (TCRR)

O preço para TCR2 Therapeutics Inc. (TCRR) é $1.48

Qual é a capitalização de mercado para TCR2 Therapeutics Inc. (TCRR)

A capitalização de mercado para TCR2 Therapeutics Inc. (TCRR) é $35.54M

Histórico de Preços de TCR2 Therapeutics Inc. (TCRR)

TCR2 Therapeutics Inc. is a clinical-stage immunotherapy firm focused on developing cutting-edge T cell receptor (TCR) therapies for cancer patients. The company's lead investigational treatment, gavo-cel, is a unique mono TCR Fusion Construct T cell (TRuC-T cell) designed to target mesothelin-positive solid tumors. This therapy is currently being evaluated in Phase I/II clinical trials for non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. Furthermore, TCR2 Therapeutics has concluded preclinical development for TC-510, another TRuC-T cell specifically engineered to target mesothelin on solid tumors. They are also advancing TC-520, a CD70-targeting TRuC-T cell designed with fratricide resistance for treating renal cell carcinoma. Founded in 2015, the company, formerly known as TCR2, Inc. until its name change in November 2016, is headquartered in Cambridge, Massachusetts.

Ano	Desempenho
2023	73.43%
2022	-78.52%
2021	-83.60%
2020	79.84%
2019	0.00%

Ano

Desempenho

2023

73.43%

2022

-78.52%

2021

-83.60%

2020

79.84%

2019

0.00%

Empresa	Preço da ação	Variação 1a%	País
Vertex Pharmaceuticals Incorporated VRTX.US	$552.07	39.99%	US
Moderna, Inc. MRNA.US	$168.77	527.63%	US
Argenx SE ARGX.US	$1.03K	56.22%	NL
CSL Limited CSL.AX	$120.74	-14.98%	AU
Lonza Group AG LONN.SW	$756.93	6.35%	CH

Empresa

Preço da ação

Variação 1a%

País